NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 137 filers reported holding NEKTAR THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 5.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,688,802 | +41.1% | 2,835,463 | +36.3% | 0.01% | +25.0% |
| Q2 2023 | $1,196,714 | +156.6% | 2,080,518 | +213.6% | 0.00% | +100.0% |
| Q1 2023 | $466,374 | +68890.2% | 663,500 | +121.7% | 0.00% | 0.0% |
| Q4 2022 | $676 | -99.9% | 299,268 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $958,000 | -15.7% | 299,268 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $1,137,000 | +1416.0% | 299,268 | +2058.0% | 0.00% | – |
| Q1 2022 | $75,000 | -59.9% | 13,868 | 0.0% | 0.00% | -100.0% |
| Q4 2021 | $187,000 | -94.3% | 13,868 | -92.9% | 0.00% | -94.4% |
| Q3 2020 | $3,259,000 | +10.9% | 196,449 | +124.5% | 0.02% | -35.7% |
| Q1 2019 | $2,940,000 | -16.5% | 87,503 | -18.3% | 0.03% | -30.0% |
| Q4 2018 | $3,521,000 | – | 107,132 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |